Gamida Cell falls as FDA extends blood cancer therapy review period

Gamida Cell

22/11/2022 12:20

** U.S. listed shares  GMDA.O  of Israeli cancer therapy
developer Gamida Cell Ltd fall ~17% premarket to $1.48; one of
the top pct losers across all three major U.S. stock indexes
    ** Company late on Monday said the U.S. Food and Drug
Administration (FDA) extended the review period for its
experimental therapy omidubicel by 3 months
    ** Gamida is developing omidubicel, an advanced cell therapy
candidate, as a potential life-saving bone marrow transplant for
patients with blood cancer
    ** FDA will now decide on the use of omidubicel by May 1,
2023 vs previous target action date of Jan. 30, 2023
    ** Up to Monday's close, stock down ~30% YTD vs 11% decline
in Nasdaq Biotechnology index  .NBI 
 (Reporting by Sriparna Roy)
 ((sriparna.roy@thomsonreuters.com))